Biomarkers predicting adverse events |
Warfarin |
Thrombosis |
CYP2C9 and VKORC1 |
Testing recommended to identify patients at risk for increased bleeding. |
Carbamazepine |
Epilepsy |
HLA‐B*1502 |
Testing recommended to identify patients at risk of toxic skin reactions. |
Abacavir |
HIV infection |
HLA‐B*5701 |
Testing recommended to identify those at risk for potentially life‐threatening hypersensitivity. |
Celecoxib |
Pain and arthritis |
CYP2C9 |
Testing may identify patients at risk for accumulating toxic levels of drug. |
Irinotecan |
Colon cancer |
UGT1A1*28 |
Testing recommended to identify patients at risk of myelo‐suppression. |
Biomarkers predicting responses |
Tamoxifen |
Breast cancer |
CYP2D6 |
Testing may identify patients resistant to treatment with tamoxifen. |
Cetuximab Panitumumab |
Colon cancer |
KRAS |
Testing may identify patients resistant to therapy with monoclonal antibodies to EGF receptors. |
Trastuzumab |
Breast cancer |
HER2 |
Testing required to identify patients suitable for Herceptin therapy. |